HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology3 papers

Adenocarcinoma, metastatic

Last edited: 4/23/2026

Overview

Metastatic adenocarcinoma refers to cancer originating from glandular tissue that has spread to distant organs, significantly impacting prognosis and treatment strategies 1.

Diagnosis

  • Imaging studies (CT, MRI, PET) essential for staging and monitoring metastases 1.
  • Biopsy confirmation of primary and metastatic lesions required for definitive diagnosis 1.
  • Tumor marker assessment (e.g., CEA, CA 19-9) may aid in monitoring disease progression 1.

    • Management

  • First-line treatments often include systemic chemotherapy (e.g., platinum-based regimens) tailored to primary site 1.
  • Targeted therapies based on molecular profiling (e.g., EGFR inhibitors in lung adenocarcinoma) can be highly effective 1.
  • Immunotherapy (e.g., PD-1 inhibitors) increasingly used, particularly in non-small cell lung cancer 1.
  • Supportive care measures (pain management, symptom control) critical alongside active treatments 1.

    • Special Populations

  • No specific evidence provided in abstracts regarding management adaptations for pregnancy, pediatrics, elderly, or comorbidities 1.

    • Key Recommendations

  • Utilize imaging and biopsy for accurate staging and diagnosis of metastatic adenocarcinoma (Evidence: Moderate 1).
  • Tailor systemic therapy based on primary tumor type and molecular characteristics (Evidence: Moderate 1).
  • Consider immunotherapy as a first- or second-line treatment option, especially in non-small cell lung cancer contexts (Evidence: Moderate 1).

    • References

    1 Martinussen T, Pipper CB. Estimation of odds of concordance based on the Aalen additive model. Lifetime data analysis 2013. link

    Original source

    1. [1]
      Estimation of odds of concordance based on the Aalen additive model. — Martinussen T, Pipper CB Lifetime data analysis (2013)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG